HCSC(SH:600378)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥2,057,715,959.56, representing an increase of 11.01% compared to ¥1,853,635,236.31 in the same period last year[4] - Net profit attributable to shareholders was ¥227,820,566.77, a slight increase of 2.37% from ¥222,536,455.34 in the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥224,850,996.92, up by 1.84% from ¥220,796,096.39 year-on-year[5] - Basic and diluted earnings per share were both ¥0.2521, reflecting a 1.57% increase from ¥0.2482 in the previous year[5] - Total revenue for Q1 2023 reached ¥2,057,715,959.56, an increase of 11.0% compared to ¥1,853,635,236.31 in Q1 2022[21] - Total operating costs for Q1 2023 were ¥1,864,979,386.82, up from ¥1,665,150,382.78 in Q1 2022, reflecting a year-over-year increase of 12.0%[21] - The total profit for Q1 2023 was CNY 249,624,947.78, compared to CNY 246,169,363.94 in Q1 2022, representing a growth of about 1.0%[22] Cash Flow and Assets - The company's cash flow from operating activities showed a net outflow of ¥49,739,204.36, worsening from a net outflow of ¥25,475,435.38 in the same period last year[5] - Current assets decreased to ¥7,973,408,806.97 in Q1 2023 from ¥8,551,279,776.96 in Q4 2022, a decline of 6.7%[18] - Total assets at the end of the reporting period were ¥14,888,621,752.74, down by 3.48% from ¥15,424,906,958.66 at the end of the previous year[5] - Cash and cash equivalents decreased to ¥2,355,381,825.75 in Q1 2023 from ¥2,689,201,101.39 in Q4 2022, a decline of 12.4%[18] - The net cash flow from operating activities for Q1 2023 was -CNY 49,739,204.36, worsening from -CNY 25,474,128.56 in Q1 2022[25] - The net cash flow from investing activities for Q1 2023 was -CNY 201,916,778.74, an improvement from -CNY 356,756,001.94 in Q1 2022[25] - The company experienced a net cash outflow from financing activities of -CNY 67,496,984.35 in Q1 2023, compared to a net inflow of CNY 156,830,068.08 in Q1 2022[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,788[9] - The controlling shareholder, China Haohua Chemical Group Co., Ltd., holds 590,198,123 shares, representing 64.75% of the total shares[10] - The top ten shareholders hold a combined total of 843,000,000 shares, accounting for approximately 93.5% of the total shares[11] - As of March 31, 2023, Yingtou Holdings Co., Ltd. holds 36,306,800 shares, with a pledge on 27,200,000 shares[10] Asset Restructuring and Corporate Actions - The company is undergoing a major asset restructuring to acquire 100% equity of Sinochem Blue Sky Group Co., Ltd., which is expected to constitute a significant asset restructuring and related party transaction[14] - The company’s stock was suspended from trading on February 1, 2023, due to the planned major asset restructuring[14] - The company’s stock resumed trading on February 15, 2023, following the completion of the necessary disclosures related to the asset restructuring[15] - The company is actively progressing with the asset acquisition, with ongoing audits and evaluations yet to be completed[15] Financial Position and Equity - Total assets amounted to ¥14,888,621,752.74 in Q1 2023, down from ¥15,424,906,958.66 in Q4 2022, representing a decrease of 3.5%[20] - Current liabilities decreased to ¥4,023,904,778.73 in Q1 2023 from ¥5,046,712,339.65 in Q4 2022, a reduction of 20.2%[19] - Non-current liabilities increased to ¥2,396,153,283.78 in Q1 2023 from ¥2,154,956,461.37 in Q4 2022, an increase of 11.2%[20] - Shareholders' equity attributable to the parent company increased to ¥8,445,815,295.75, a growth of 3.00% from ¥8,200,195,429.26 year-on-year[5] - Shareholders' equity rose to ¥8,468,563,690.23 in Q1 2023, compared to ¥8,223,238,157.64 in Q4 2022, reflecting an increase of 3.0%[20] Judicial and Regulatory Matters - The company reported a judicial freeze on a total of 24,366,612 shares held by its controlling shareholder, with various court orders in effect until late 2024[12][13] - The company has not disclosed any significant changes in its financial audit opinion for the first quarter of 2023[17] Research and Development - Research and development expenses for Q1 2023 amounted to CNY 135,277,270.04, slightly up from CNY 133,009,846.04 in Q1 2022[22]